News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 4, 2024

Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer

A medical expert discusses efficacy of approaches such as carboplatin doublets, checkpoint inhibitors, and PARP inhibitors for patients with platinum sensitive and platinum-resistant ovarian cancer.

Episodes in this series

EP. 1 NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

EP. 1 NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

Video 1 - "NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer"

EP. 2 NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 3 Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 4 MIRASOL trial and DESTINY-PanTumor02 Trial Overview

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 5 Tailored Therapy: Decision Making for Ovarian Cancer Treatment

Video 5 - "Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment"

EP. 6 Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment

Video 6 - "Closing Thoughts on the Current Ovarian Cancer Treatment Landscape"

EP. 7 Closing Thoughts on the Current Ovarian Cancer Treatment Landscape

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Katherine Tobon

Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP

ByBrooke McCormick,Katherine Tobon, PharmD, BCOP

February 7th 2026

Even After 6 Years, Disease Progression Impacts Survival in Mantle Cell Lymphoma

February 6th 2026

Acalabrutinib | Image Credit: © Сергей Шиманович-stocka.dobe.com.jpeg

Real-World Evidence Backs Acalabrutinib in CLL Care

ByMaggie L. Shaw

February 6th 2026

Debates at the International Stroke Conference 2026 centered on optimal treatment of ischemic stroke in the modern era. | Image credit: Aliaksandr Marko - stock.adobe.com

Is Less More After Thrombolysis? Debating Intensive Stroke Monitoring at ISC 2026

February 6th 2026

Dr Susan Vadaparampil

Linking Community Screening Programs to Cancer Centers Boosts Trial Diversity: Susan Vadaparampil, PhD, MPH

ByBrooke McCormick,Susan Vadaparampil, PhD, MPH

February 6th 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Trending on AJMC

As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”

TrumpRx Launch Brings Savings—and Uncertainty

Exploring Identity, Appearance Experiences Among Patients With Alopecia

Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP

Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text